Latest Articles
Triple Threat: Co-occurrence of Serous Borderline Ovarian Tumor, Endometrial Adenocarcinoma, and Low-Grade Appendiceal Mucinous Neoplasms With Pseudomyxoma Peritonei in a Single Patient - Cureus
Triple Threat: Co-occurrence of Serous Borderline Ovarian Tumor, Endometrial Adenocarcinoma, and Low-Grade Appendiceal Mucinous Neoplasms With Pseudomyxoma Peritonei in a Single Patient Cureus
Published: July 20, 2025, 7:43 a.m.
ASCO Reading Room | More Precise Treatments for Rare Uterine Tumors - MedPage Today
ASCO Reading Room | More Precise Treatments for Rare Uterine Tumors MedPage Today
Published: July 9, 2025, 3:13 p.m.
Chennai pvt hospital relieves woman with 2 tumorous wombs of pain - dtnext
Chennai pvt hospital relieves woman with 2 tumorous wombs of pain dtnext
Published: June 26, 2025, 1:20 a.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - BioSpace
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial BioSpace
Published: June 2, 2025, 11:48 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - GlobeNewswire
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial GlobeNewswire
Published: June 2, 2025, 6:32 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - Yahoo Finance
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial Yahoo Finance
Published: June 2, 2025, 6:30 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - Yahoo
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial Yahoo
Published: June 2, 2025, 6:30 p.m.
Serous Borderline Ovarian Tumor and Extensive Abdominopelvic Endometriosis Mimicking Advanced Epithelial Ovarian Cancer in a Postmenopausal Patient - Frontiers
Serous Borderline Ovarian Tumor and Extensive Abdominopelvic Endometriosis Mimicking Advanced Epithelial Ovarian Cancer in a Postmenopausal Patient Frontiers
Published: May 16, 2025, 7:47 p.m.
DNA glycosylase (NEIL3) overexpression associated with low tumor immune infiltration and poor overall patient survival in endometrial cancer - Nature
DNA glycosylase (NEIL3) overexpression associated with low tumor immune infiltration and poor overall patient survival in endometrial cancer Nature
Published: May 10, 2025, 10:19 a.m.
Depo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects - AboutLawsuits.com
Depo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects AboutLawsuits.com
Published: April 22, 2025, 4 p.m.
Link copied to clipboard!